Document is current

Any future updates will be listed below

Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue

Crossref DOI link: https://doi.org/10.1007/16833_2022_54

Published Online: 2022-10-28

Published Print: 2022

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark